HECA, a crucial protein in lymphocyte trafficking and homing, is regulated by a series of chemical activators that influence its activity through various signaling pathways. Forskolin, through its activation of adenylate cyclase, elevates intracellular cAMP levels, subsequently enhancing PKA activity. This activation cascade indirectly promotes HECA's functional role in guiding lymphocytes to their targeted locations. Similarly, PMA and Ionomycin, by activating PKC and increasing intracellular calcium levels respectively, modulate signaling pathways that directly influence HECA's interactions with endothelial cells, crucial for lymphocyte adhesion and migration. Sphingosine-1-Phosphate, engaging with its receptors, initiates signaling that can further augment HECA's role in lymphocyte egress, an essential step in immune surveillance. Moreover, the phosphodiesterase 4 inhibitor Rolipram, by increasing cAMP levels, indirectly potentiates HECA's activity in the immune response.
Further refining the regulation of HECA are compounds that modulate specific signaling pathways. BAY 11-7082, an NF-κB inhibitor, alters inflammatory response pathways, thereby indirectly enhancing HECA's involvement in lymphocyte trafficking during inflammation. Similarly, SB203580 and U0126, inhibitors of p38 MAPK and MEK1/2 respectively, shift signaling dynamics in a manner that favors HECA's role in lymphocyte migration. The PI3K inhibitors LY294002 and Wortmannin, by altering PI3K-dependent pathways, contribute to the modulation of HECA's activity in lymphocyte adhesion and migration. The calcium ionophore A23187 further supports this regulation by increasing intracellular calcium, which is pivotal in activating pathways influencing HECA's function. Lastly, Staurosporine, despite its broad kinase inhibition spectrum, may indirectly enhance HECA's role by affecting specific kinases involved in lymphocyte adhesion and trafficking. Collectively, these activators orchestrate a complex regulatory network, fine-tuning HECA's pivotal role in the immune system.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylate cyclase, increasing cAMP levels and thereby enhancing PKA activity. This elevation indirectly promotes HECA's role in lymphocyte migration and homing. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates Protein Kinase C (PKC), modulating HECA's interaction with ligands on endothelial cells and enhancing its role in lymphocyte adhesion and trafficking. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Functions as a calcium ionophore, increasing intracellular calcium levels and activating calcium-dependent kinases and phosphatases, which can enhance HECA's functional activity in lymphocyte adhesion. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Binds to its receptors to initiate signaling pathways influencing lymphocyte egress from lymphoid organs, thus enhancing HECA's role in trafficking and migration of lymphocytes. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Inhibits phosphodiesterase 4, leading to an increase in cAMP levels and enhancement of PKA activity, subsequently increasing HECA's involvement in lymphocyte adhesion and migration. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Inhibits NF-κB activation, modulating the activity of HECA in lymphocyte adhesion and migration, particularly in inflammatory conditions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that shifts signaling pathways towards those favoring HECA's involvement in lymphocyte trafficking. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK1/2 in the MAPK pathway, potentially enhancing HECA's function in lymphocyte migration by affecting signaling pathways that regulate its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can modulate signaling pathways to indirectly enhance HECA's functional role in lymphocyte adhesion and migration. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, affecting PI3K-dependent signaling pathways and potentially enhancing HECA's role in lymphocyte migration and homing. | ||||||